SOURCE: Kalorama Information

Kalorama Information

March 19, 2010 12:17 ET

Report: Growth of ISH Testing Exceeds Other Novel Technologies

NEW YORK, NY--(Marketwire - March 19, 2010) -  ISH tests or in situ hybridization tests, which are probes for specific DNA sequences performed on portions of tumor tissue, have become one of the fastest growing market segments in laboratory medicine, showing eight percent sales growth per year. With new enhancements the technology will continue to drive revenues for Abbott, Genzyme, Invitrogen and myriad other test makers, according to a report from healthcare market research publisher Kalorama Information. Its biennial report on the cancer industry, "The Worldwide Market for Cancer Diagnostics," notes that ISH has performed better than other technologies that were predicted to dominate the industry. 

"ISH is carving out a growing market share because of its usefulness for a variety of cancer markers including ER, PSA, EGFR and Her-2," said Shara Rosen, senior diagnostic analyst for Kalorama Information. "It has outperformed expectations made for it in the last decade and shown more growth so far than other celebrated areas such as microarrays and DNA assays."

The world market for all ISH (Silver, chromogenic or fluorescent) is estimated by Kalorama Information to be $670 million in 2009. Vendor sales are made up mostly of individual antibodies or probes and instrumentation to automate the staining and reading of slides, along with digital imaging systems and data analysis software in high-end systems. It is these systems, which offer automated sample preparation and digital analysis instrumentation that Kalorama Information believes will continue to put ISH in a leadership position, allowing for same-day biopsy results and better patient care.

"The technology is moving from manual and operator-read to automated and digitally interpreted," said Rosen. "ISH testing used to be qualitative and inherently subjective, resulting in significant deficiencies in the interpretation of test results, but automation has made it more relevant." 

The new automation has also allowed some movement of histology from hospital and reference laboratories to large physician practices in the U.S. Digital imaging can convert entire microscope slides into high-resolution digital slides. Thus, digitized images of an entire slide can be analyzed, stored and remotely viewed on computer monitors located anywhere. This digital capability sets the stage for pathology telemedicine and small bench top systems for small labs and physician office laboratories as well as labs in rural areas.

"The Worldwide Market for Cancer Diagnostics" contains more information on the cancer testing industry including other technologies, market forecasts and detailed company profiles. For more information:

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter ( and LinkedIn (

Contact Information